Tell the FDA to Reverse Its Approval of SSRIs for Hot Flashes!

A recent study has found that the SSRI antidepressant paroxetine—which is FDA-approved for the treatment of hot flashes—may increase the risk of breast cancer.

The FDA approved Brisdelle as an opportunity to provide women with a non-hormonal alternative to synthetic hormone replacement therapy for hot flashes, because the latter can increase the risk of breast cancer. Women who suffer from hot flashes are the most at-risk group for breast cancer.

Now that there is evidence the new drug may promote breast cancer, the FDA should reverse its irresponsible approval of Brisdelle—the trade name for this drug—immediately.

Please personalize your message, if you have the time!


  • Stephen Ostroff


*Required fields


Dear [Decision Maker],

[Your Name]
[Your Address]
[City, State ZIP]